Cargando…

International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States

The objective of this study was to analyze information on pediatric use in Korean drug product labels and compare it with that in US Food and Drug Administration (FDA) labeling information. Prescription information on pediatric use contained in the commonly used drugs’ product labels approved by Kor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Yun‐Kyoung, Han, Nayoung, Burckart, Gilbert J., Oh, Jung Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028218/ https://www.ncbi.nlm.nih.gov/pubmed/31544241 http://dx.doi.org/10.1002/cpt.1640

Ejemplares similares

A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
por: Hoshino, Yuko, et al.
Publicado: (2022)

Evaluation of off-label medication use and drug safety in a pediatric intensive care unit
por: Lee, Soojin, et al.
Publicado: (2023)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han, Nayoung, et al.
Publicado: (2021)

Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States
por: Cho, Inhye, et al.
Publicado: (2022)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Frequency of prescriptions of off-label drugs and drugs not approved for pediatric use in primary health care in a southern municipality of Brazil
por: Gonçalves, Marcele Giacomin, et al.
Publicado: (2016)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Regulation of Pharmacogene Expression by microRNA in The Cancer Genome Atlas (TCGA) Research Network
por: Han, Nayoung, et al.
Publicado: (2017)

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels
por: Schultz-Knudsen, Katrine, et al.
Publicado: (2020)

Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021)

Analysis of Issues and Future Trends Impacting Drug Safety in South Korea
por: Kim, Myeong Gyu, et al.
Publicado: (2019)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
por: Abulwerdi, Gelareh A., et al.
Publicado: (2023)

Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study
por: Mostaghim, Sana R, et al.
Publicado: (2017)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
por: Stanek, Eric J., et al.
Publicado: (2013)

Off-label drugs use in pediatric palliative care
por: De Zen, Lucia, et al.
Publicado: (2018)

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
por: Kim, Kyoung Kon
Publicado: (2019)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness
por: Boyce, Richard D, et al.
Publicado: (2013)

Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information
por: Jang, Ha Young, et al.
Publicado: (2022)

Safety Consequences of Off-Label Drugs Used for COVID-19
por: Dasgupta, Nabarun
Publicado: (2021)

Ciprofloxacin Use in Hospitalized Children: Approved or Off-label?
por: Faghihi, Toktam, et al.
Publicado: (2017)

Findings on In Vitro Transporter-Mediated Drug Interactions and Their Follow-Up Actions for Labeling: Analysis of Drugs Approved by US FDA between 2017 and 2021
por: Lee, Kyeong-Ryoon, et al.
Publicado: (2022)

Guideline for the management of pediatric off-label use of drugs in China (2021)
por: Meng, Min, et al.
Publicado: (2022)

Label-free drug discovery
por: Fang, Ye
Publicado: (2014)

Off-label drugs for obesity
por: Morgan, Andy, et al.
Publicado: (2022)

Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
por: Hsieh, Julie, et al.
Publicado: (2022)

Confusing the drug facts on one nonprescription drug label with those on another: The Drug Facts Label as a text schema
por: Ryan, Michael P, et al.
Publicado: (2016)

Evaluation of Drug Labels Following the 2015 Pregnancy and Lactation Labeling Rule
por: Byrne, John J., et al.
Publicado: (2020)

A questionnaire-based study in Calabria on the knowledge of off-label drugs in pediatrics
por: Saullo, Francesca, et al.
Publicado: (2013)

Gap between pediatric and adult approvals of molecular targeted drugs
por: Nishiwaki, Satoshi, et al.
Publicado: (2020)

Off-label Drug Prescription Pattern and Related Adverse Drug Reactions in the Medical Intensive Care Unit
por: Raut, Asawari, et al.
Publicado: (2021)

Pharmacogenetic information for patients on drug labels
por: Haga, Susanne B, et al.
Publicado: (2014)

Off-label drugs for weight management
por: Hendricks, Ed J
Publicado: (2017)

Pharmaceutical excipients and the information on drug labels
por: Balbani, Aracy Pereira Silveira, et al.
Publicado: (2015)

Collective exposure to lead from an approved natural product-derived drug in Korea
por: Lim, Dae-Young, et al.
Publicado: (2019)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use
por: Pesiou, Stella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lo3e1q62rr0r0ihug1jpmk6gdl